Nicholas G Minutolo
Overview
Explore the profile of Nicholas G Minutolo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smole A, Benton A, Poussin M, Eiva M, Mezzanotte C, Camisa B, et al.
Cancer Cell
. 2022 Dec;
40(12):1470-1487.e7.
PMID: 36513049
Despite the success of CAR-T cell cancer immunotherapy, challenges in efficacy and safety remain. Investigators have begun to enhance CAR-T cells with the expression of accessory molecules to address these...
2.
Shaw L, Poussin M, Rodriguez-Garcia A, Eggold J, Minutolo N, Wang J, et al.
Blood Adv
. 2022 Sep;
7(9):1885-1898.
PMID: 36053778
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoid malignancies associated with poor prognosis due to ineffective treatment options and high rates of relapse. The success of chimeric antigen...
3.
Zappala F, Higbee-Dempsey E, Jang B, Miller J, Yan L, Minutolo N, et al.
Sci Adv
. 2022 May;
8(18):eabn4613.
PMID: 35522741
Extensive antibody engineering and cloning is typically required to generate new bispecific antibodies. Made-to-order genes, advanced expression systems, and high-efficiency cloning can simplify and accelerate this process, but it still...
4.
Rodriguez-Garcia A, Lynn R, Poussin M, Eiva M, Shaw L, OConnor R, et al.
Nat Commun
. 2021 Feb;
12(1):877.
PMID: 33563975
The immunosuppressive tumor microenvironment (TME) represents a major barrier for effective immunotherapy. Tumor-associated macrophages (TAMs) are highly heterogeneous and plastic cell components of the TME which can either promote tumor...
5.
Anderson N, Minutolo N, Gill S, Klichinsky M
Cancer Res
. 2020 Nov;
81(5):1201-1208.
PMID: 33203697
Adoptive cell therapy with genetically modified T cells has generated exciting outcomes in hematologic malignancies, but its application to solid tumors has proven challenging. This gap has spurred the investigation...
6.
Minutolo N, Sharma P, Poussin M, Shaw L, Brown D, Hollander E, et al.
J Am Chem Soc
. 2020 Mar;
142(14):6554-6568.
PMID: 32191035
Universal immune receptors represent a rapidly emerging form of adoptive T-cell therapy with the potential to overcome safety and antigen escape challenges faced by conventional chimeric antigen receptor (CAR) T-cell...
7.
Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu A, Minutolo N, Gitto S, et al.
Mol Ther
. 2019 Dec;
28(2):548-560.
PMID: 31870622
The prognosis of patients diagnosed with advanced ovarian or endometrial cancer remains poor, and effective therapeutic strategies are limited. The Müllerian inhibiting substance type 2 receptor (MISIIR) is a transforming...
8.
Minutolo N, Hollander E, Powell Jr D
Front Oncol
. 2019 Apr;
9:176.
PMID: 30984613
Chimeric antigen receptor (CAR) T cells have shown great success in the treatment of CD19+ hematological malignancies, leading to their recent approval by the FDA as a new cancer treatment...
9.
Rodriguez-Garcia A, Minutolo N, Robinson J, Powell D
Gynecol Oncol
. 2017 Apr;
145(3):426-435.
PMID: 28377094
Immunotherapies have achieved remarkable success in treating different forms of cancer including melanoma, non-small cell lung carcinoma, bladder cancer, synovial cell sarcoma, and multiple myeloma using immune checkpoint blockade or...